sepsis or its subset, bacteremia, represents a leading cause of death in the United States. Moreover, recent national vital statistics data about the entity of septicemia show that this condition was listed as the fourteenth most common cause of death (it ranked ninth in the age group of 1-4 years and tenth in the age group of >65 years) [1] .
If the average bloodstream infection entails an additional 5-10 days in the hospital at a cost of $ 1,000/day, the direct costs nationally would be $1 billion to $4 billion each year. It is likely that this estimate of the economic burden is conservative. Recently, two new monoclonal antibodies with activity against the core glycolipid of gram-negative-rod endotoxin have been tested [3, 4] . Because their cost is anticipated to be high (approximately $3,000 to $4,000/ course), a great deal of, attention is being focused on these products. Each showed protective effects in selected subsets of the test populations. In an important development, one of the products has been released for use in three countries in Europe at a cost of $3,700/dose, and a review of both by the U.S. Food and Drug Administration (FDA) is pending. The economic burden of routine use of expensive monoclonal antibodies for therapy for suspected sepsis will be significant if and when these or others are approved for use in the United States. The purpose of this communication is to review the indications for the current use of monoclonal antibodies in therapy for gram-negative sepsis and to suggest guidelines for their use clinically.
The pathogenesis of sepsis involves the release of endotoxin (core glycolipid) from the external surface of the bacteria, which in turn triggers a response from the macrophage [5] . This has been referred to as the sepsis cascade, because rapid progression of the disease involves multiple feedback mechanisms. The macrophage elaborates a number of cytokines, including tumor necrosis factor and various interleukins [6] , an event which directly leads to the sepsis syn- * The APACHE-II scores are not comparable since they represent only 57% of E5 patients, all of whom were evaluated just prior to receiving the drug (whereas the HA-1A patients were evaluated on the first day in the intensive care unit, regardless of the time of enrollment in the study).
drome. Thus, it has been reasoned that interruption of the endotoxin stimuli may prevent or favorably modify the outcome of the infection.
Support for this hypothesis came from a study by Ziegler and colleagues [7] that showed polyclonal human plasma had a protective effect in therapy for sepsis. The active sera protected patients who had sepsis, whether or not they had bacteremia and whether or not they were in shock. Subsequently, polyclonal antibody protected patients in the intensive care unit from the effects of shock and lethal shock when administered prophylactically [8] . Although in one study a polyclonal IgG preparation directed at endotoxin failed to protect when given therapeutically to patients in septic shock [9] , two monoclonal IgM preparations showed some evidence of effecting a more favorable outcome in two other studies [3, 4] . An outline of the latter two studies is shown in table 1.
In the study reported by Ziegler et al. [3] , there was no difference in effect when the two populations that had been randomized to receive the active agent (HA-1 A)or the placebo were compared. However, when the subset of patients with bacteremia was examined, a better survival rate was noted among those receiving the monoclonal antibody than among the placebo recipients. The improved survival occurred whether or not patients were in shock. In the study reported by Greenman et al. [4] , again no difference in effect was noted when two populations that had been randomized to receive either an active agent (E5) or a placebo were compared. However, when the subset of patients without refractory shock was examined, the survival rate among those receiving the monoclonal antibody was significantly improved as compared with that among placebo recipients. The improved survival occurred whether or not patients were bacteremic. Thus, different subsets of patients in the two clinical trials seemed to benefit from the monoclonal antibodies.
To summarize, it is curious that the bacteremic HA-1A recipients had an improved rate of survival as compared with that of placebo recipients, whether or not they were in shock, yet nonbacteremic patients who received HA-IA fared no better than placebo recipients. In the trial with E5, patients NOTE. This analysis is based on published studies only; a separate FDA analysis of the HA-1A trial and a second trial of E5 antibody (in abstract form) raise questions as to the adequacy with which a reduction in mortality rate has been demonstrated.
* Includes patients with and without bacteremia, but the data are not statistically significant for each subgroup. NOTE. 4, = decreased; Base def = base deficit; t = increased; PT = prothrombin time; PTT = partial thromboplastin time; CI = cardiac index; SVR = systemic vascular resistance; WBCs = white blood cells; GNRs = gram-negative rods. who were not in shock and received active drug had a better rate of survival than placebo recipients, whether or not they were bacteremic, yet patients in shock who received E5 fared no better than placebo recipients (table 2) .
It is useful to review the entrance criteria for the two published studies testing monoclonal antibodies [3, 4] ; these criteria are listed in table 3.
There were some differences in definitions used for baseline and outcome measures (table 4) that may have obscured the similarities of the populations in the two studies.
The reasons for developing guidelines for the clinical use of monoclonal antibodies include their great expense (approximately $3,000 to $4,000/dose), their apparent efficacy only in subsets of the study populations, and the fact that the definitions used in the two published studies are not in concordance. The uncertainties regarding the relative and absolute merits of expensive therapies at a time of soaring health care costs have prompted the development of these guidelines.
In both studies [3, 4] , the analysis of the data in terms of the intention to treat principle, which is of critical importance to the practicing clinician, failed to show any significant reduction in mortality among all patients treated with a monoclonal antibody. In each study, the subset of patients who appeared to benefit (200 [37% of 543] with gram-negative bacteremia in the HA-1A study and 137 [29% of 468] with gram-negative sepsis and no shock in the E5 study) represented a minority of the total population of patients treated. Lastly, conclusive evidence for reduction of the mortality rate with use of endotoxin antibodies is not available. These issues raise serious concerns about the widespread use of expensive monoclonal antibodies in patients with the "sepsis syndrome" [10] when fewer than 50% of such patients might stand to benefit.
We recommend that the following guidelines be considered before either monoclonal antibody is given.
( I) The monoclonal antibody should be used only when there is strong clinical suspicion and/or laboratory evidence that sepsis is likely due to gram-negative bacilli. The proper use of gram stains would be helpful. Clinical or laboratory parameters that would heighten suspicion include positive blood cultures, identification or isolation of gram-negative bacilli from documented sites of infection, a focus of infection commonly associated with gram-negative bacteria (such as pyelonephritis, peritonitis, nosocomial pneumonia, abdominal or pelvic abscess, or cholangitis), and absence of other causes of sepsis (gram-positive organisms or fungi).
(2) All hypotensive patients should have received at least 500 mL of intravenous isotonic fluid and should show unresponsiveness to fluid replacement before administration of monoclonal antibodies is considered. Note that simple hypotension (systolic blood pressure <90 mm Hg) should not be a criterion for use.
(3) Evidence of organ dysfunction should be present, such as pulmonary infiltrates, hypoxia, and normal wedge pressure; renal or hepatic dysfunction; disseminated intravascular coagulation; or acute change in CNS function.
(4) All patients receiving monoclonal antibodies should be ill enough to require treatment in units where intensive care can be administered.
(5) The importance of supportive care and appropriate antibiotics is emphasized. The patients should receive antibiotics to which the likely pathogens are susceptible in in vitro tests. Each institution should have available a profile of common bloodstream pathogens and most-effective antibiotics.
(6) No patient should receive the drug if there is a history of allergy to the agent or a closely related agent. Patients who are given either antibody should be observed carefully for evidence of short-and long-term immune or toxic reactions, which may become increasingly recognized as experience with these agents accumulates.
Conclusion
It is the opinion of the Infectious Diseases Society of America (IDSA) that, at face value, both antiendotoxin monoclonal antibodies are only of possible benefit. Specifically, reduction of the mortality rate with use of such monoclonal antibodies has not been conclusively established in the studies published to date. If and when they become available in hospital pharmacies, these agents should be used sparingly and only in patients who are most likely to benefit clinically. As new information accrues from clinical trials or analyses of the data from such trials, the IDSA guidelines for use of monoclonal antibodies will be updated progressively.
